Skip to main content
. Author manuscript; available in PMC: 2015 Jul 29.
Published in final edited form as: Pharmacotherapy. 2012 Jan;32(1):e1–e6. doi: 10.1002/PHAR.1003

Figure 1.

Figure 1

(A) Steady-state maraviroc log concentration–time curve after a 300-mg dose (given at time 0) in the case patient (solid squares) compared with previously reported steady-state maraviroc log concentration–time curves after repeated maraviroc doses of 300 mg every 12 hours in subjects with normal renal and hepatic function (open diamonds).3 (B) Steady-state raltegravir log concentration–time curve after a 400-mg dose (given at time 0) in the case patient (solid squares) compared with previously reported steady-state raltegravir log concentration–time curves after repeated raltegravir doses of 400 mg every 12 hours in subjects with normal renal and hepatic function (open diamonds).5